Peer-Reviewed Paper Confirms BioLargo's Advanced Oxidation System Safely Removes Micropollutants from Wastewater

WESTMINSTER, CA / ACCESSWIRE / January 4, 2021 / BioLargo, Inc. (OTCQB:BLGO), developer of cutting-edge environmental technologies and a full-service engineering company, announced the publication of a peer-reviewed scientific paper in the Journal of Environmental Management confirming that the energy-efficient and cost-effective Advanced Oxidation System (AOS) water disinfection system also safely removes certain micropollutants from municipal wastewater. The paper concludes that the AOS is "a promising and environmentally friendly technology for wastewater treatment, remediation, and management", highlighting the additional value the AOS can provide customers by addressing an important and poorly served technical need in the water industry. Dr. Greg Goss, in the Faculty of Science at the University of Alberta and the researcher who led the study, commented "The AOS is a major technological breakthrough for the treatment of micropollutants."

Micropollutants are widespread synthetic chemicals that end up in municipal water supplies around the world. They originate from pharmaceuticals, personal care products, detergents, pesticides and more, and are linked to ecological damage and human health issues. They are distinct from other water contaminants because they are difficult and expensive to remove using conventional technologies such as UV, ozone, and biological treatment.

The need for cost-effective treatment of micropollutants in water and wastewater is well recognized in the water industry. One significant issue with municipal wastewater is the feminization of fish in the receiving environment due the presence of endocrine disrupting chemicals (EDC) such as estradiol. This paper reports that the BioLargo AOS effectively removes the EDC effects of estradiol commonly present in municipal wastewater. The other micropollutant tested in the study, benzo[a]pyrene, is regulated by the EPA pursuant to the Safe Water Drinking Act. The U.S. EPA maintains a published list of "contaminants of emerging concern" that includes a number of additional micropollutants in municipal wastewater that may cause ecological or human health impacts, but are not yet regulated. As regulatory scrutiny continues to increase surrounding micropollutants, municipalities are seeking technologies that can affordably and safely remove them from their wastewater streams to prevent surface water contamination.

BioLargo's ground-breaking and patented Advanced Oxidation System (AOS) is a water treatment platform that provides high-level disinfection and consumes less electricity than competing technologies. The AOS' ability to eliminate the deleterious effects of micropollutants in wastewater offers significant additional value to the municipal wastewater treatment market by providing affordable and effective micropollutant removal in addition to its primary use as an energy-efficient and cost-effective wastewater disinfection technology.

Two significant commercial-scale AOS projects are starting in the coming year. The first, at a municipal wastewater treatment plant near Montreal, Canada, will assess the AOS' ability to efficiently disinfect and remove micropollutants and other organic contaminants at an operating municipal wastewater treatment plant. The second will treat poultry-processing wastewater at a certified organic farm in Alberta, Canada. The development of the AOS, and both pilot projects, are being led by BioLargo's Alberta, Canada, based subsidiary, BioLargo Water. In addition to these two commercial-scale pilot projects, BioLargo is now screening potential distributors in North America.

Dr. Richard Smith, President of BioLargo Water, commented, "We will be shipping our first commercial-scale AOS unit in the coming weeks to the wastewater treatment plant near Montreal, and will install our first full-scale ‘zero liquid discharge' system in our project with Sunworks Farms in Alberta in the first half of 2021. These initial projects will help demonstrate the substantial value the AOS provides in wastewater treatment, and we believe will ultimately lead to significant market adoption."

To read the peer-reviewed published paper, visit: https://authors.elsevier.com/a/1cHo114Z6telDf.

Highlights from the paper:

• AOS is highly effective at eliminating the negative effects of two particularly difficult micropollutants, suggesting it may be effective against a wide range of similar compounds.
• The AOS requires extremely low levels of electric energy to operate.
• The AOS did not increase toxicity or introduce additional hazards (i.e., decontamination by-products) in the post-treatment effluent.

This work was funded in part by the Canadian Natural Science and Engineering Research Council (NSERC) and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

To learn more about BioLargo Water and the AOS, visit www.biolargowater.com and the website of its parent company BioLargo at www.biolargo.com.

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to "make life better". We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) developed the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

SOURCE: BioLargo, Inc.